Is sorafenib plus interferon α2b safe and effective in patents with renal cell carcinoma?

被引：4
|
作者：
Rini, Brian I. [1 ]
机构：
[1] Cleveland Clin, Dept Solid Tumor Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
NATURE CLINICAL PRACTICE UROLOGY | 2008年 / 5卷 / 03期
关键词：
combination; efficacy; interferon alpha; renal cell carcinoma; sorafenib;
D O I：
10.1038/ncpuro1036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
  • [41] Acute interstitial pneumonia caused by interleukin-2 and interferon α-2b therapy for renal cell carcinoma: a case report and clinical study
    Zhang Hanyu
    Xie Miaorong
    中华医学杂志（英文版）, 2014, (23) : 4154 - 4156
  • [42] Sorafenib and sunitinib in renal cell carcinoma
    Stein, Mark N.
    Flaherty, Keith T.
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3765 - 3770
  • [43] BEVACIZUMAB PLUS INTERFERON AS FIRST LINE: TREATMENT IN RENAL CELL CARCINOMA
    Baldi, Licia
    Pagano, Maria
    Boni, Corrado
    ANTICANCER RESEARCH, 2014, 34 (05) : 2665 - 2666
  • [44] Response to interferon alpha 2B plus ribavirin in hepatitis C infected patients who failed interferon alpha 2B monotherapy.
    King, JW
    Favrot, DR
    Shakhashiro, A
    Gholson, CF
    Balart, LA
    Achord, J
    Kirkikis, JA
    Lyles, WE
    Hollier, JD
    Srinivas, D
    HEPATOLOGY, 1998, 28 (04) : 708A - 708A
  • [45] Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma
    Lümmen, G
    Sperling, H
    Luboldt, H
    Otto, T
    Rübben, H
    UROLOGIA INTERNATIONALIS, 1998, 61 (04) : 215 - 219
  • [46] Five-year survival analysis of interferon-a plus sorafenib versus sorafenib monotherapy as first-line treatment for metastatic clear cell renal cell carcinoma.
    Ding-Wei, Ye
    Hai-Lang, Zhang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [47] Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo
    Chen, Shiyou
    Liang, Lunan
    Wang, Ying
    Diao, Jianhun
    Zhao, Chunxiong
    Chen, Gang
    He, Yunfeng
    Luo, Chunli
    Wu, Xiaohou
    Zhang, Yao
    MOLECULAR MEDICINE REPORTS, 2015, 12 (05) : 6727 - 6737
  • [48] Tumor Treating Fields (TTFields) Plus Sorafenib Is Safe and Effective in Hepatocellular Carcinoma Tested in Vitro and in an Animal Model
    Davidi, S.
    Brami, C. Tempel
    Munster, M.
    Gotlib, K.
    Zeevi, E.
    Schneiderman, R. S.
    Voloshin, T.
    Giladi, M.
    Kinzel, A.
    Kirson, E.
    Weinberg, U.
    Palti, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E675 - E676
  • [49] Sorafenib combined with radiofrequency ablation in the treatment of a patient with renal cell carcinoma plus primary hepatocellular carcinoma
    Gang, Guo
    Yu Hongkai
    Xu, Zhang
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 1088 - 1089
  • [50] Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma
    Huesken, A. C.
    Tsianakas, A.
    Hensen, P.
    Nashan, D.
    Loquai, C.
    Beissert, S.
    Luger, T. A.
    Sunderkoetter, C.
    Schiller, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (01) : 71 - 78
12345